{"groups":[{"description":"Participants received 20 milligrams (mg) panobinostat thrice a week (TIW), 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"FG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat twice a week (BIW), 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"FG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"FG002","title":"Arm C - Panobinostat (10 mg, TIW)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"83"}],"comment":"Full analysis set (FAS): all participants to whom study treatment was assigned by randomization.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"82"},{"groupId":"FG002","numSubjects":"80"}],"comment":"Safety Set: all participants who received any study treatment.","type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"83"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}